 Maria Amaya
Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 17 | 2026 | 685 | 3.000 |
Why?
| | STAT3 Transcription Factor | 2 | 2025 | 205 | 1.420 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 12 | 2026 | 279 | 1.130 |
Why?
| | Neoplastic Stem Cells | 6 | 2025 | 407 | 1.090 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2025 | 15 | 0.900 |
Why?
| | Sulfonamides | 12 | 2026 | 579 | 0.900 |
Why?
| | Mitochondria | 3 | 2026 | 984 | 0.720 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.710 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2026 | 1961 | 0.710 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 47 | 0.700 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 167 | 0.640 |
Why?
| | Bendamustine Hydrochloride | 1 | 2020 | 17 | 0.630 |
Why?
| | Azacitidine | 5 | 2026 | 157 | 0.590 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2024 | 71 | 0.580 |
Why?
| | Rituximab | 1 | 2020 | 211 | 0.580 |
Why?
| | Signal Transduction | 3 | 2025 | 5185 | 0.570 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 134 | 0.570 |
Why?
| | Immunoconjugates | 1 | 2020 | 138 | 0.550 |
Why?
| | Antineoplastic Agents | 4 | 2026 | 2201 | 0.480 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 2 | 2013 | 31 | 0.460 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 437 | 0.440 |
Why?
| | Antibodies, Monoclonal | 2 | 2020 | 1505 | 0.410 |
Why?
| | gamma-Globins | 1 | 2013 | 1 | 0.390 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2025 | 127 | 0.390 |
Why?
| | Fetal Hemoglobin | 1 | 2013 | 8 | 0.390 |
Why?
| | Erythroid Cells | 1 | 2013 | 8 | 0.390 |
Why?
| | Gene Silencing | 2 | 2013 | 202 | 0.380 |
Why?
| | Cell Survival | 3 | 2026 | 1092 | 0.360 |
Why?
| | Autoantigens | 1 | 2013 | 425 | 0.310 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 677 | 0.300 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 419 | 0.300 |
Why?
| | Calcium | 2 | 2025 | 1182 | 0.280 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2025 | 881 | 0.270 |
Why?
| | Oxidative Phosphorylation | 3 | 2026 | 209 | 0.270 |
Why?
| | Glutaredoxins | 1 | 2026 | 15 | 0.240 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2026 | 46 | 0.230 |
Why?
| | Mutation | 4 | 2026 | 4081 | 0.210 |
Why?
| | Myelodysplastic Syndromes | 1 | 2026 | 147 | 0.210 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.210 |
Why?
| | Leukemia, Myeloid, Chronic-Phase | 1 | 2024 | 3 | 0.210 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2591 | 0.200 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2024 | 103 | 0.190 |
Why?
| | Tumor Cells, Cultured | 5 | 2022 | 881 | 0.190 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 186 | 0.190 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3523 | 0.190 |
Why?
| | Humans | 31 | 2026 | 144667 | 0.180 |
Why?
| | Protein Kinase Inhibitors | 2 | 2025 | 971 | 0.170 |
Why?
| | Phosphorylation | 1 | 2025 | 1704 | 0.160 |
Why?
| | Mice | 7 | 2026 | 18261 | 0.160 |
Why?
| | Prognosis | 4 | 2025 | 4312 | 0.160 |
Why?
| | Repressor Proteins | 3 | 2013 | 428 | 0.160 |
Why?
| | Lipase | 1 | 2020 | 75 | 0.160 |
Why?
| | Animals | 11 | 2026 | 37948 | 0.150 |
Why?
| | Recurrence | 2 | 2023 | 1136 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2026 | 11735 | 0.140 |
Why?
| | Macrophages | 1 | 2026 | 1496 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 269 | 0.140 |
Why?
| | Leukemia | 1 | 2020 | 245 | 0.140 |
Why?
| | Triazines | 1 | 2018 | 49 | 0.130 |
Why?
| | Thromboplastin | 4 | 2002 | 64 | 0.130 |
Why?
| | Aminopyridines | 1 | 2018 | 129 | 0.130 |
Why?
| | Water Pollution, Chemical | 1 | 2016 | 5 | 0.120 |
Why?
| | Water Quality | 1 | 2016 | 37 | 0.120 |
Why?
| | Coal Mining | 1 | 2016 | 23 | 0.120 |
Why?
| | Groundwater | 1 | 2016 | 41 | 0.120 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1319 | 0.110 |
Why?
| | Blast Crisis | 2 | 2025 | 34 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2024 | 741 | 0.100 |
Why?
| | Adult | 8 | 2025 | 40489 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1742 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1145 | 0.100 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2013 | 138 | 0.090 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 87 | 0.090 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2013 | 77 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2026 | 2037 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1889 | 0.090 |
Why?
| | Melanoma | 3 | 2002 | 757 | 0.080 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 631 | 0.080 |
Why?
| | Platelet Activation | 2 | 2008 | 98 | 0.080 |
Why?
| | Aged | 7 | 2026 | 25955 | 0.080 |
Why?
| | Mice, Transgenic | 2 | 2013 | 2184 | 0.080 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 129 | 0.080 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2009 | 23 | 0.070 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 44 | 0.070 |
Why?
| | Minisatellite Repeats | 1 | 2009 | 36 | 0.070 |
Why?
| | Models, Molecular | 2 | 2011 | 1610 | 0.070 |
Why?
| | Carrier Proteins | 1 | 2013 | 733 | 0.070 |
Why?
| | Middle Aged | 7 | 2026 | 35971 | 0.070 |
Why?
| | Antigen-Antibody Complex | 1 | 2008 | 70 | 0.070 |
Why?
| | Receptors, IgG | 1 | 2008 | 76 | 0.070 |
Why?
| | Neoplasm Proteins | 2 | 2001 | 441 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2009 | 347 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 669 | 0.060 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2026 | 23 | 0.060 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2009 | 248 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2013 | 4110 | 0.060 |
Why?
| | Male | 7 | 2026 | 72431 | 0.060 |
Why?
| | Remission Induction | 1 | 2026 | 309 | 0.060 |
Why?
| | Phagocytosis | 1 | 2026 | 296 | 0.050 |
Why?
| | Thrombosis | 1 | 2008 | 396 | 0.050 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 388 | 0.050 |
Why?
| | Female | 7 | 2026 | 78304 | 0.050 |
Why?
| | GTP Phosphohydrolases | 1 | 2024 | 93 | 0.050 |
Why?
| | Philadelphia Chromosome | 1 | 2024 | 18 | 0.050 |
Why?
| | Glutathione | 1 | 2026 | 366 | 0.050 |
Why?
| | Young Adult | 4 | 2024 | 14122 | 0.050 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2024 | 68 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1484 | 0.050 |
Why?
| | Neuraminidase | 1 | 2003 | 25 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8284 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 88 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2024 | 315 | 0.050 |
Why?
| | Trypanosoma cruzi | 1 | 2003 | 39 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2026 | 4539 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 139 | 0.050 |
Why?
| | Tyrosine | 1 | 2003 | 219 | 0.050 |
Why?
| | CD40 Ligand | 1 | 2002 | 39 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2024 | 263 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2023 | 190 | 0.040 |
Why?
| | CD40 Antigens | 1 | 2002 | 89 | 0.040 |
Why?
| | Glycoproteins | 1 | 2003 | 353 | 0.040 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2001 | 69 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17149 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2002 | 268 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 87 | 0.040 |
Why?
| | Monocytes | 1 | 2002 | 536 | 0.040 |
Why?
| | Blood Platelets | 1 | 2002 | 379 | 0.040 |
Why?
| | Pentoxifylline | 1 | 1998 | 23 | 0.040 |
Why?
| | Endothelial Growth Factors | 1 | 1998 | 62 | 0.040 |
Why?
| | Hemoglobins | 1 | 2001 | 381 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 1998 | 82 | 0.030 |
Why?
| | Lymphokines | 1 | 1998 | 128 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2024 | 1159 | 0.030 |
Why?
| | Transcriptome | 1 | 2024 | 1036 | 0.030 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2001 | 260 | 0.030 |
Why?
| | Neoplasms, Experimental | 1 | 1998 | 167 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1766 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3147 | 0.030 |
Why?
| | Environmental Restoration and Remediation | 1 | 2016 | 9 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 587 | 0.030 |
Why?
| | Ohio | 1 | 2016 | 145 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 729 | 0.030 |
Why?
| | Stem Cells | 1 | 2020 | 621 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2847 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2001 | 1437 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2020 | 2489 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2008 | 550 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2011 | 147 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2010 | 36 | 0.020 |
Why?
| | Static Electricity | 1 | 2010 | 114 | 0.020 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2010 | 66 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 507 | 0.020 |
Why?
| | Methylation | 1 | 2010 | 241 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2010 | 247 | 0.020 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 187 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 393 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2010 | 392 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 5967 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 473 | 0.020 |
Why?
| | DNA Fingerprinting | 1 | 2009 | 32 | 0.020 |
Why?
| | Adolescent | 2 | 2024 | 22409 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 73 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1161 | 0.020 |
Why?
| | Drosophila Proteins | 1 | 2010 | 213 | 0.020 |
Why?
| | Drosophila melanogaster | 1 | 2010 | 237 | 0.020 |
Why?
| | Child | 2 | 2024 | 22600 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 849 | 0.020 |
Why?
| | Bevacizumab | 1 | 2008 | 168 | 0.020 |
Why?
| | Up-Regulation | 2 | 2002 | 848 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2009 | 516 | 0.020 |
Why?
| | Heparin | 1 | 2008 | 243 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2136 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2909 | 0.010 |
Why?
| | DNA Methylation | 1 | 2011 | 664 | 0.010 |
Why?
| | Histones | 1 | 2010 | 663 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1847 | 0.010 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2003 | 179 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2008 | 990 | 0.010 |
Why?
| | Catalysis | 1 | 2003 | 319 | 0.010 |
Why?
| | Solubility | 1 | 2002 | 236 | 0.010 |
Why?
| | Factor VII | 1 | 2001 | 24 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2003 | 762 | 0.010 |
Why?
| | Chromatography, Affinity | 1 | 2001 | 80 | 0.010 |
Why?
| | Factor VIIa | 1 | 2001 | 43 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 42 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 2001 | 52 | 0.010 |
Why?
| | Dimerization | 1 | 2001 | 190 | 0.010 |
Why?
| | Factor Xa | 1 | 2001 | 34 | 0.010 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2001 | 48 | 0.010 |
Why?
| | Cell Communication | 1 | 2002 | 325 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2001 | 317 | 0.010 |
Why?
| | Kinetics | 1 | 2003 | 1602 | 0.010 |
Why?
| | Antibodies | 1 | 2001 | 396 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1363 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 1998 | 78 | 0.010 |
Why?
| | Cell Hypoxia | 1 | 1998 | 248 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2001 | 1154 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6399 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 1998 | 691 | 0.010 |
Why?
| | Protein Binding | 1 | 2001 | 2243 | 0.010 |
Why?
| | Infant | 1 | 2009 | 10023 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 11790 | 0.010 |
Why?
| | United States | 1 | 2009 | 16018 | 0.010 |
Why?
| | Rats | 1 | 1998 | 5570 | 0.000 |
Why?
|
|
Amaya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|